Researchers have found a possible early detection method for dementia in individuals with type 2 diabetes and cardiovascular disease. That is great news for patients, but it could work out in more ways than one. A handful of companies have tried to develop Alzheimer's disease drugs, but none have been successful. The study results could provide pharmaceutical companies with a new patient population for mild to moderate Alzheimer's disease therapies. Additionally, perhaps studying the disease before it is clinically diagnosed will lead to powerful insights for its progression. In the following video, Fool contributor Maxx Chatsko explains the ramifications for several companies.
Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and biotechnology.
The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.